TCV-309 chloride is primarily utilized in the field of medical research, particularly in studies related to gastrointestinal motility. It functions as a potent and selective antagonist for cholecystokinin (CCK) receptors, specifically the CCK-A subtype. This property makes it a valuable tool in investigating the role of CCK in digestive processes, such as gallbladder contraction and pancreatic enzyme secretion. Additionally, TCV-309 chloride has been employed in experimental models to explore its potential therapeutic applications in conditions like irritable bowel syndrome (IBS) and other motility disorders. Its ability to modulate CCK signaling pathways also contributes to research on appetite regulation and satiety mechanisms, offering insights into potential treatments for obesity and related metabolic disorders.